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Objective: Compression stockings are widely applied after acute proximal deep vein thrombosis, but their efficacy in
preventing the post-thrombotic syndrome remains controversial. This study assessed the effect of prolonged compression
therapy after a standard treatment of 6 months after acute deep vein thrombosis.
Methods: Of 900 patients screened, we randomly allocated 169 patients with a first or recurrent proximal deep vein
thrombosis after receiving 6 months of standard treatment to wear compression stockings or not. Primary efficacy
analysis was performed on the end point of emerging skin changes (C4-C6 according to the CEAP classification).
Secondary analysis was done on symptoms associated with post-thrombotic syndrome. All analyses were done according
to the intention-to-treat principle.
Results: The primary end point occurred in 11 patients (13.1%) in the treatment group compared with 17 (20.0%) in the
control group (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.28-1.28; P .19).Mean follow-upwas 3.2 years
and 2.9 years, respectively. Five additional patients in the control group required compression therapy owing to
post-thrombotic signs and symptoms not included in the primary end point. No venous ulceration was observed in either
group. Within subgroup analyses of the primary end point, we observed a large sex-specific difference between women
(HR, 0.11; 95% CI, 0.02-0.91) and men (HR, 1.07; 95% CI, 0.42-2.73). Symptom relief was significant in favor of
compression treatment during the first year but not thereafter.
Conclusion: Prolonged compression therapy after proximal deep vein thrombosis significantly reduces symptoms andmay
prevent post-thrombotic skin changes. Whether these findings translate to the prevention of advanced disease states with
ulcerations remains unclear. ( J Vasc Surg 2008;47:1015-21.)Clinical research in the field of venous thromboembolism
in recent years has focusedmainly on diagnostic strategies and
drug regimens in the early- and middle-term stage of the
disease.1-3 The long-term course of the disease has received
less scientific attention, although its main manifestation—
post-thrombotic syndrome (PTS)—has potential important
implications for patients and society because of substantial
consumption of health care resources.4
The reported incidence of PTS varies widely between
5% (most2 to 4 years)5 and 50% (mostfirst 6months).6
An important reason for this discrepancy is the lack of a
generally accepted definition of PTS, which range from
clinical signs with trophic skin changes5 to a suggestion of
mixed scores with clinical signs and symptoms.6-8 Other
reasons for the discrepancy are differences in populations
and settings with respect to the extension of deep vein
thrombosis (DVT) and different treatment strategies for
the acute disease.5-7,9
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doi:10.1016/j.jvs.2008.01.008So far, only three randomized controlled trials (RCT)
concerning compression therapy for the prevention of PTS
have been conducted.6-8 The investigators of two larger
RCTs reported effect sizes of about 50% risk reductions in
favor of compression.6,7 One smaller trial used placebo-
stockings as a control and found no benefit of compres-
sion.8 These trials incorporated symptoms into their defi-
nition of the primary end point. Early symptoms, however,
may be due to an acute or subacute DVT and are not yet a
sign of PTS.10 Incorporating early symptoms after DVT
into the outcome definition of PTS therefore leads to an
apparently high incidence of end points. Furthermore,
efficacy assessment of compression therapy should differen-
tiate between symptoms of DVT, which decline over time,
and symptoms that persist or evolve as a part of the “full
clinical picture” of PTS.
In contrast with previous trials, we aimed to address the
genuine effect of stockings to prevent PTS.We randomized
patients only 6 months after the initial diagnosis and treat-
ment of DVT and introduced end point definitions that are
carefully based on clinical signs (ie, skin changes as a
surrogate marker) and symptoms.
METHODS
Patients. Recruitment period lasted from June 1997
until June 2004. Patients who were generally symptomatic
were initially referred by hospital interns or primary care
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of DVT. All patients with confirmed DVT completed a
recommended standard therapy before screening for study
inclusion. Therapy consisted of heparin in the initial phase,
followed by oral anticoagulation (target international nor-
malized ratio 2.0 to 3.0) and compression stockings (ankle
pressure, 26.3 to 36.1 mm Hg) for at least 6 months.
Medical care in this prestudy period was provided by the
primary care physician. After finishing these 6 months of
therapy, patients were screened for study inclusion. Inclu-
sion criteria were age 18 years and first or recurrent
proximal DVT confirmed by duplex ultrasound (DUS)
imaging. Proximal DVT was defined as thrombosis of the
popliteal vein or more proximal (eg, femoral and iliac vein).
Exclusion criteria were chronic venous insufficiency C4 to
C6 by the CEAP classification (corresponding to skin
changes ascribed to venous disease with or without active
or healed ulcer),11 advanced malignancy or death antici-
pated to occur2 years, long-lasting immobilization, geo-
graphic inaccessibility, dementia, peripheral arterial disease
contraindicating compression therapy, anticipated lack of
compliance, or refused informed consent.
Treatment allocation to compression stocking (inter-
vention) or no stocking (control) was concealed and per-
formed by a study nurse not involved in the trial by means
of a computer-generated randomization list. Subsequent
medical care, including exceptional oral anticoagulation
6-months standard treatment period was left to the dis-
cretion of the primary care physician. The single-center trial
was approved by the local ethical committee, and informed
consent was obtained from all patients before to inclusion.
Baseline examination. At study inclusion, DUS im-
aging of the affected leg was performed in all patients by
one experienced investigator (C. J.). The deep venous
system, consisting of the common femoral vein, proximal
femoral vein, popliteal vein and posterior tibial vein, and
themain superficial trunks (great and small saphenous vein)
were evaluated for patency and presence of reflux. Patency
was divided into three categories: open, partially, and com-
pletely occluded.
Reflux was tested with a standardized compression/
decompression method, as described elsewhere.12,13
Pathologic reflux was defined as a more than twofold
normal reflux time in the deep vein segments13 and 1
second reflux time in the superficial veins. The clinical
assessment included the examination of the malleolar region
for the presence of hyperpigmentation, eczema, atrophie
blanche, dermatoliposclerosis, or ulceration.Amedical history
for the presence of five PTS-associated symptoms accurately
described in a study by Widmer et al14 as pain, heaviness,
sensation of heat, tension, and tiredness of the affected limb
was taken, and additional diagnoses were recorded.
Intervention. Patients in the intervention group were
reinstructed about wearing compression stockings during
the day, defined as from getting up in the morning until
bedtime. Prescribed stockings were bought by the patients
and reimbursed for up to two pairs per year by their
insurance companies. The type of recommended stockingwas a ready-to-wear, flat-knitted, below knee stocking with
an applied pressure at the ankle of 26.3 to 36.1 mm Hg.
Follow-up examinations. Clinical follow-up exami-
nations, as described for baseline, were done by three
specialists in vascular medicine who were blinded to the
results of the DUS examination but not for treatment
allocation. Follow-up examinations took place every 3
months in the first year after inclusion and every 6 months
thereafter until an end point developed or the patient
reached the end of follow-up. When recurrent DVT was
suspected, DUS imaging was performed. Criteria for diag-
nosing recurrent DVT were (1) noncompressibility of a
previously not affected vein segment, (2) elevated throm-
botic burden in a previously thrombosed segment com-
pared with the findings at entry, or (3) the presence of a
floating thrombus tip. Patients with recurrent DVT during
follow-up were censored from further analyses because of
the need for compression stocking.
Adherence to treatment. Adherence to wearing the
stocking (or not wearing in the control group) was verified
by a study nurse at every visit. Full adherence was defined if
a patient acknowledged wearing the stocking for 6 days
per week, partial adherence for 4 to 5 days, and nonadher-
ence for 4 days a week.
Outcome. The primary end point was defined as the
occurrence of emerging post-thrombotic skin changes ac-
cording to C4 or higher. Any skin-related end point de-
tected for the first time had to be confirmed by a consensus
of two outcome assessors at a second visit 3 months later.
This second date was used as the event date for analysis. The
secondary end point focused on PTS-associated symptoms.
Symptom status was registered at every follow-up visit. A
patient was considered symptomatic if at least one of five
PTS-associated symptoms was present. In all patients of the
control group who resumed using compression stockings
during follow-up, the exact reason for compression, such as
swelling of the leg or pain, was registered. All patients in the
control group who developed post-thrombotic skin
changes according to C4 or higher were encouraged to
wear compression stockings to avoid progression of chronic
venous insufficiency.
Statistical analysis. At the time our trial was started,
little information about the incidence of PTS was available.
We calculated a sample size assuming a 45% incidence of
PTS in the control group over an average follow-up dura-
tion of 3 years, with an assumed 50% relative risk reduction
of compression stockings and a dropout of 10%. With 80%
power and a two-sided significance level of P  .05, 85
patients were needed per treatment arm.
No interim analyses were performed. Primary efficacy
analysis was done according to the intention-to-treat prin-
ciple using the end point of emerging post-thrombotic skin
changes. Kaplan-Meier analysis with the log-rank test was
used to test the null hypothesis of equality of the survival
curves for the intervention and control arm. We performed
extended analyses on the primary outcome with adjustment
for baseline covariates with Cox regression. The prespeci-
fied predictor variables were ipsilateral previous DVT, the
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reflux at baseline DUS imaging at the same leg, age, and
sex. Completeness of follow-up was calculated as suggested
by Clark.15 We conducted subgroup analyses for the pre-
specified predictor variables by testing interactions with
treatment in the Cox model.16
To deal with treatment crossover during follow-up, we
additionally performed an as-treated analysis using time-
dependent covariates. We used the counting process nota-
tion of the Cox model and reallocated patients in the
intervention group who stopped wearing the stocking to
the control group thereafter, and vice versa for the control
group patients who started to wear a stocking.
A repeatedmeasurement analysis to assess differences in
the presence or absence of symptoms during follow-up was
performed according to treatment allocation (analysis of
secondary end points). Amarginal generalized linear model
of repeated follow-up measurements within a patient was
used.17 The baseline symptom status was included as a
covariate in themodel, and an interaction of treatment with
time reflected potential change of treatment on symptoms
over time. A crude as well as adjusted analysis including
the same prespecified covariates as with the primary end
point analysis was performed. We used R 2.1.1 software
(The R Foundation for Statistical Computing, http://
www.r-project.org/foundation/) for all statistical anal-
Fig 1. Trial profile. CVI, Chronic venous insufficiency C4 to C6
(CEAP classification)10; DVT, proximal deep vein thrombosis.
*Other reasons included frailty, dementia, and living too remote
from the study center.yses.RESULTS
A total of 900 consecutive patients with proximal DVT
were screened. Of these, 593 were excluded for clinical
reasons and 138 were considered noncompliant or refused
to give informed consent (Fig 1). The latter group was
similar to the study population concerning age, sex, and
thrombus extension. The intention-to-treat population
consisted of 169 patients, 84 of whom were randomized to
the intervention group and 85 to the control group. The
number of patients lost to follow-up was similar in both
groups, and 62 patients completed the trial as intended in
each group. Table I reports the distribution of baseline
characteristics according to treatment allocation. Some
baseline imbalances were recognized for sex and same-leg
previous DVT. Completeness of follow-up was 84.5% in
the intervention group and 75.4% in the control group.
Mean length of follow-up was 3.2 years (range, 2 months-
6.8 years) in the intervention group and 2.9 years (range,
1.5 months-7.0 years) in the control group.
Primary end point. Overall, the primary end point
developed in 11 patients (13.1%) in the intervention group,
and in 17 (20.0%) in the control group. Two of the 17
patients in the control group with post-thrombotic skin
changes developed C4b with dermatoliposclerosis, no pa-
tients in either group developed venous ulcer (C5). Three
patients in each group died (Table II). Kaplan-Meier curves
for rates of freedom from post-thrombotic skin changes are
Table I. Baseline characteristics of patients included
Characteristics
Intervention
(n  84)
Control
(n  85)
Age, median (IQR) years 64.1 (52.9-72.5) 63.8 (45.3-70.8)
Sex, No. (%)
Male 54 (64.3) 45 (52.9)
Female 30 (35.7) 40 (47.1)
BMI, median (IQR)
kg/m2 25.6 (24.2-28.7) 25.9 (22.9-28.1)
Side of DVT, No. (%)
Left 49 (58.3) 44 (51.8)
Right 35 (41.7) 41 (48.2)
Previous DVT, No. (%)a
No DVT 63 (75.0) 68 (80.0)
Same Leg 18 (21.4) 13 (15.3)
Contralateral leg 2 (2.4) 4 (4.7)
Location of DVT,
No. (%)
Popliteal 26 (30.9) 29 (34.1)
Popliteal and femoral 44 (52.4) 38 (44.7)
Popliteal, femoral, and
iliac 14 (16.7) 18 (21.2)
DUS finding in any vein
segment, No. (%)
Obstruction 50 (59.5) 49 (57.6)
Reflux 79 (94.0) 82 (96.5)
Obstruction and reflux 49 (58.3) 51 (60.0)
Obstruction or reflux 81 (96.4) 83 (97.6)
BMI, Body mass index; DUS, duplex ultrasound; DVT, proximal deep vein
thrombosis; IQR, interquartile range.
aOne value missing in the intervention group.given for both treatment arms for the whole study popula-
variat
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intention-to-treat analysis, the relative hazard for the pri-
mary end point of intervention against control was 0.60
(95% confidence interval [CI], 0.28-1.28, P  .19) and
after adjustment for baseline imbalances 0.61 (95% CI,
0.28-1.31, P  .20; Table II).
Seven patients in each group had a crossover from their
assigned treatment. Five of the seven crossovers in the control
Table II. Primary end point
Intervention (n  84) Control (n  8
PT-s, crude effect 11 (13.1%) 17 (20.0%)
PT-s, adjustedc
CI, Confidence interval; HR, hazard ratio; PT-s, post-thrombotic skin chan
aHazard ratio from Cox model, intention to treat analysis.
bHazard ratio from Cox model, as-treated (treatment as time-dependent co
cAdjusted for previous deep vein thrombosis, age, and sex.
Fig 2. Kaplan-Meier estimates of survival without post-throm-
botic skin changes in the intervention (dotted line) and control
groups (dashed line). A, Survival free of post-thrombotic skin
changes for the whole study population. B, Treatment effects
specific to men. C, Treatment effects specific to women.group were caused by development of post-thrombotic pain,swelling, or venous claudication, and all the remaining in both
groups were because of patients’ wishes. The median time
of crossover was early in the control group at a median 4
months (range, 3-7 months) but late in the intervention
group at 33 months (range, 3-56 months). In the as-
treated analysis, the unadjusted relative hazard for the
primary end point of intervention vs control was 0.65 (95%
CI, 0.31-1.40; P  .27; Table II).
Subgroup analyses for the primary end point showed
that the stocking effect was significantly different within
gender strata but not within strata of the remaining pre-
specified covariates. Although men did not show any ben-
efit from the intervention (hazard ratio, 1.07; 95% CI,
0.42-2.73), women showed a significant benefit (hazard
ratio, 0.11; 95% CI, 0.02-0.91; Figs 2 and 3). Baseline
characteristics, including body mass index as well as side
and extent of DVT, were equally distributed in men and
women.
Secondary end point. In 12.2% (77 of 629) of
follow-up visits in the intervention group and 16.5% (93 of
563) of follow-up visits in the control group, patients
reported on at least one of the five PTS associated symp-
HRa (95% CI) P HRb (95% CI) P
0.60 (0.28-1.28) .19 0.65 (0.31-1.40) .27
0.61 (0.28-1.31) .20 0.65 (0.30-1.42) .28
e).
Fig 3. Subgroup-analysis of primary end point. CI, Confidence
interval; DVT, ipsilateral deep vein thrombosis; HR, hazard ratio.5)
ges.toms at any follow-up visit occasion. In both groups, there
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first 12 months (Fig 4). After an initial 65% relative risk
reduction (odds ratio [OR], 0.35; 95% CI, 0.17-0.73) by
the intervention at 3 months, the effect decreased to 54%
(OR, 0.46; 95% CI, 0.23-0.90) at 1 year. Thereafter, no
reduction in symptom complaints was registered in either
group.
Adherence. In the intervention group, nonadherence to
stocking treatment was recorded at 8.4% of follow-up visits.
Men indicated in 11% and women in 3.6% of follow-up visits
nonadherence to compression stocking treatment. Modeling
noncompliance as a function of sex showed that noncompli-
ance was about four timesmore frequent inmen than women
(OR, 4.1; 95% CI, 1.0-16.0; P .05).
DISCUSSION
This open, randomized controlled trial investigated the
long-term benefit of compression stockings beyond the 6
months of standard compression after DVT of the lower
extremities. Unlike two previous trials,6,7 this study did not
begin immediately after the diagnosis of DVT, where com-
pression therapy was considered mandatory. In addition,
only post-thrombotic skin changes based on the standard-
ized C-part of the CEAP classification11 were used in this
study for the definition of the primary end point. Although
post-thrombotic skin changes were reduced by 40%, this
finding did not reach statistical significance. Nevertheless,
the observed effect size was close to that obtained in the
two main previous trials of similar size and comparable
applied compression pressure as our study, as well as a
Cochrane review, where a risk reduction of about 50% for
all degrees of severity of PTS was reported.6,7,18
We need to emphasize several important differences in
the trial concepts that may further explain the findings of
our trial. The trials of Brandjes et al7 and Prandoni et al6
used scoring systems based on the combination of different
clinical signs and symptoms. We instead used the CEAP
classification11 for assessment of post-thrombotic skin
changes for the primary end point. To our knowledge, this
now generally accepted classification of chronic venous
Fig 4. Probability of presence of symptoms over time in controls
(circles) and intervention group (crosses). Symptom presence
means at least one of five symptoms present at any follow-up
examination. Error bars indicate 95% confidence interval per treat-
ment arm.changes19,20 has not yet been used in comparable PTSintervention trials. Our rationale was to have amore reliably
measurable end point that is less prone to misclassification.
To strengthen the primary end point and to avoid
misinterpretation of acute and subacute DVT symptoms as
PTS, we did not incorporate symptoms in the primary end
point. Our primary end point thus relied explicitly on
post-thrombotic skin changes, and symptoms were ana-
lyzed as a secondary end point. Symptoms such as cramps,
pruritus, paraesthesia, or “heaviness” are very unspecific21
and are probably not suitable to describe long-term conse-
quences in a cohort. This is underlined by the rapid de-
crease of symptoms during the first year and the prevalence
of symptoms of about 10% during extended follow-up in
our study. Furthermore, edema of the foot or calf region
and redness or pain in the calf, as incorporated in scoring
systems for the definition of PTS, are also unspecific.6,7
During the early course of thromboembolism, they may
represent rather symptoms and signs of acute or subacute
DVT rather than those of PTS. The inclusion of these
clinical signs into widely accepted diagnostic scores for
acute DVT, such as the Wells-Score, may underline this
fact.22
The CEAP classification has also some limitations and
may lack discrimination because it does not allow for a
more detailed grading of the severity of skin lesions. Differ-
entiation betweenmild, moderate, or severe PTS, as used in
the work of Brandjes et al7 and Prandoni et al,6 is not
provided. This drawback was recently ameliorated by a
refined classification that now allows the differentiation
between pigmentation or eczema (4a) and lipodermato-
sclerosis or atrophy blanche (4b), or both, the more ad-
vanced stage of chronic venous insufficiency.23
We considered only skin alterations according to C4a
and C4b or higher as the primary end point, although
others have defined less specific C2 and C3 as mild PTS.24
This restriction inevitably results in a lower incidence of the
primary end point. The rational behind our decision is that
in large epidemiologic studies of asymptomatic individuals
without a history of DVT, manifestations of C1 to C3 were
found in more than 80%.25,26 In our opinion, these mostly
harmless venous alterations are not sufficiently relevant to
justify their classification as true PTS.
Finally, we based our subgroup analyses on a priori set
hypothesis and showed no difference in the primary end
point for all prespecified treatment covariates but sex. In
women, but not in men, stockings were highly effective in
the prevention of post-thrombotic skin alterations. The
incidence of end points in the control group was not sex
specific, however. A possible but perhaps not the only
explanation of this differential effect is lower adherence of
men to compression stocking therapy.
The strength of the presented study is that enrolment
only started 6 months after the diagnosis of DVT, with the
aim that signs and symptoms related to PTS are less con-
taminated with signs and symptoms of the acute disease. By
using DUS imaging for the assessment of the whole venous
system, we were able to document post-thrombotic dam-
age of the veins in almost all of the included patients, which
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We did not include patients with a distal DVT to avoid a
lower risk population for PTS but did include patients with
previous DVT assuming that they present an increased risk
for PTS. We used an approach to treatment that is very
close to real life by using ready-to-wear stockings and
leaving final responsibility for replacement of stockings to
the patient. Finally, in contrast with previous studies, the
standardized well-established CEAP scoring system was
used to classify disease.
Our study does have several limitations. In particular, it
lacks adequate power to show a significant difference for
the primary outcome. Several factors may have restricted
the power of this trial. Our primary end point definition led
to a much lower number of events. Furthermore, the
inclusion criteria led to the selection of a population of
patients with less advanced skin alterations, where the
compression therapy might be less effective than in more
advanced C categories. The relatively large number of
patients not eligible for the trial might also limit a general-
ized application of our findings to other populations with
DVT.
Although a good adherence was documented, the ther-
apeutic effect of the intervention was additionally diluted
by poorer adherence, particularly in men. Furthermore, the
five crossover patients in the control group who resumed
wearing stockings owing to symptomatic PTS were not
considered in our primary end point even though they
presented the classical type of PTS but without progressive
skin changes. Themortality rate in our trial was much lower
than in those of Brandjes et al7 and Prandoni et al,6 which
is in the line with the strict exclusion criteria.
Patients were not blinded because the nature of the
intervention precluded effective blinding of patients
through placebo stockings. They all had a 6-month expe-
rience with verum stockings, so that the application of sham
stockings was not an alternative. Blinding of outcome
assessors was not done because an experienced outcome
assessor would certainly identify typical skin imprints in-
duced by compression stockings, even if we had advised
patients in the intervention group to abstain from wearing
stockings at the day of the clinical visit.
CONCLUSION
We found that prolonged compression therapy by
ready-to-wear compression stockings may reduce post-
thrombotic skin changes, an objective early sign of PTS, by
about 40% compared with noncompression. Our trial,
however, was insufficiently powered to demonstrate a sta-
tistically significant effect. We found an additional effect of
symptom reduction from prolonged compression therapy
in the early phase of the study. The efficacy of treatment in
men and women differed to a great extent. In our study
population, women—but not men—showed a benefit
from compression therapy; however, owing to the uncer-
tainty of subgroup results, this effect has to be treated with
caution and needs future attention. Our compliance data,
underlined by a low and equally distributed number ofcrossovers, indicate that a fairly good acceptance of this
harmless but effective therapy can be anticipated with a
minimal effort of two short visits a year. Finally, identifica-
tion of a high-risk patient population for the development
of PTS, which probably could profit most from prolonged
compression therapy, should be the focus of future studies.
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